Free Trial

This company has been marked as potentially delisted and may not be actively trading.

Medicis Pharmaceutical (MRX) Competitors

Medicis Pharmaceutical logo

MRX vs. CBOE, BXP, CIB, FHN, SF, OHI, EVR, AFG, GL, and LINE

Should you be buying Medicis Pharmaceutical stock or one of its competitors? The main competitors of Medicis Pharmaceutical include Cboe Global Markets (CBOE), BXP (BXP), BanColombia (CIB), First Horizon (FHN), Stifel Financial (SF), Omega Healthcare Investors (OHI), Evercore (EVR), American Financial Group (AFG), Globe Life (GL), and Lineage (LINE). These companies are all part of the "finance" sector.

Medicis Pharmaceutical vs. Its Competitors

Medicis Pharmaceutical (NYSE:MRX) and Cboe Global Markets (NASDAQ:CBOE) are both finance companies, but which is the superior investment? We will compare the two businesses based on the strength of their earnings, media sentiment, risk, dividends, profitability, analyst recommendations, institutional ownership and valuation.

82.7% of Cboe Global Markets shares are owned by institutional investors. 3.8% of Medicis Pharmaceutical shares are owned by company insiders. Comparatively, 0.2% of Cboe Global Markets shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Cboe Global Markets has higher revenue and earnings than Medicis Pharmaceutical.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Medicis Pharmaceutical$1.24B2.18$141.30MN/AN/A
Cboe Global Markets$4.09B5.95$764.90M$7.6330.48

In the previous week, Cboe Global Markets had 17 more articles in the media than Medicis Pharmaceutical. MarketBeat recorded 17 mentions for Cboe Global Markets and 0 mentions for Medicis Pharmaceutical. Cboe Global Markets' average media sentiment score of 1.27 beat Medicis Pharmaceutical's score of 0.00 indicating that Cboe Global Markets is being referred to more favorably in the news media.

Company Overall Sentiment
Medicis Pharmaceutical Neutral
Cboe Global Markets Positive

Cboe Global Markets has a net margin of 18.64% compared to Medicis Pharmaceutical's net margin of 0.00%. Cboe Global Markets' return on equity of 22.02% beat Medicis Pharmaceutical's return on equity.

Company Net Margins Return on Equity Return on Assets
Medicis PharmaceuticalN/A N/A N/A
Cboe Global Markets 18.64%22.02%10.73%

Medicis Pharmaceutical currently has a consensus target price of $44.00, indicating a potential upside of 13.86%. Cboe Global Markets has a consensus target price of $221.75, indicating a potential downside of 4.64%. Given Medicis Pharmaceutical's stronger consensus rating and higher probable upside, research analysts clearly believe Medicis Pharmaceutical is more favorable than Cboe Global Markets.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Medicis Pharmaceutical
0 Sell rating(s)
2 Hold rating(s)
5 Buy rating(s)
0 Strong Buy rating(s)
2.71
Cboe Global Markets
3 Sell rating(s)
8 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
1.92

Medicis Pharmaceutical pays an annual dividend of $0.56 per share and has a dividend yield of 1.4%. Cboe Global Markets pays an annual dividend of $2.52 per share and has a dividend yield of 1.1%. Cboe Global Markets pays out 33.0% of its earnings in the form of a dividend. Cboe Global Markets has raised its dividend for 1 consecutive years.

Summary

Cboe Global Markets beats Medicis Pharmaceutical on 10 of the 16 factors compared between the two stocks.

Get Medicis Pharmaceutical News Delivered to You Automatically

Sign up to receive the latest news and ratings for MRX and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding MRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

MRX vs. The Competition

MetricMedicis PharmaceuticalSecurity & commodity brokers IndustryFinance SectorNYSE Exchange
Market Cap$2.73B$24.35B$11.87B$20.45B
Dividend Yield1.44%1.09%5.53%3.72%
P/E RatioN/A16.1019.9727.80
Price / Sales2.185.9525.7149.81
Price / CashN/A19.4218.7218.22
Price / BookN/A5.692.264.58
Net Income$141.30M$764.90M$990.08M$982.91M

Medicis Pharmaceutical Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
MRX
Medicis Pharmaceutical
0.6853 of 5 stars
$38.65
+18.8%
$44.00
+13.9%
+99.4%$2.73B$1.24B0.002,074
CBOE
Cboe Global Markets
3.013 of 5 stars
$233.21
+1.8%
$219.64
-5.8%
N/A$24.42B$4.09B32.301,540Positive News
Analyst Forecast
BXP
BXP
3.7149 of 5 stars
$67.44
-1.7%
$79.54
+17.9%
+11.7%$10.86B$3.41B-3,370.31780News Coverage
CIB
BanColombia
1.8541 of 5 stars
$46.21
+2.5%
$39.00
-15.6%
+35.8%$10.84B$10.55B7.4134,114
FHN
First Horizon
4.5878 of 5 stars
$21.23
+0.9%
$22.53
+6.1%
+43.2%$10.67B$5.03B14.747,252Positive News
Analyst Forecast
SF
Stifel Financial
4.3659 of 5 stars
$103.98
+0.3%
$105.50
+1.5%
+30.5%$10.65B$4.97B19.889,000Positive News
Analyst Downgrade
OHI
Omega Healthcare Investors
4.4896 of 5 stars
$36.63
+0.1%
$41.88
+14.3%
+7.7%$10.59B$1.05B22.7550Positive News
EVR
Evercore
3.9118 of 5 stars
$270.85
+0.7%
$250.57
-7.5%
+33.4%$10.52B$2.98B25.922,380Analyst Forecast
AFG
American Financial Group
4.5737 of 5 stars
$126.32
+1.1%
$139.33
+10.3%
+5.7%$10.45B$8.32B13.278,700
GL
Globe Life
4.6564 of 5 stars
$124.43
+0.4%
$137.73
+10.7%
+48.7%$10.23B$5.78B10.123,732Analyst Forecast
LINE
Lineage
4.523 of 5 stars
$43.52
-1.3%
$62.10
+42.7%
N/A$10.08B$5.34B-13.5226,000

Related Companies and Tools


This page (NYSE:MRX) was last updated on 7/8/2025 by MarketBeat.com Staff
From Our Partners